Instrument Inactif

Autres langues Venn Life Sciences Holdings London S.E.

Actions

Creo extends contract; Belluscura raises funds	02/07
HVIVO plc Announces Change of Registered Address	02/07
HVIVO plc Announces Phase 2b Influenza Field Study Contract	02/07
HVIVO says Omicron contract validates move to Canary Wharf facility	03/06
HVIVO plc Signs £2.5 Million Contract with A Mid-Sized Pharmaceutical Company to Initiate an Omicron characterization study	03/06
HVIVO swings to profit and commences annual dividends as outlook rosy	09/04
HVIVO plc Provides Revenue Guidance for the Year 2024	09/04
HVIVO plc Reports Earnings Results for the Full Year Ended December 31, 2023	09/04
European Green Transition starts trading on London's AIM market	08/04
Investment firm European Green Transition plans listing on AIM	18/03
HVIVO Chair and non-exec director sell 30.0 million shares	14/02
Hvivo Completes Secondary Placing	14/02
HVIVO directors to sell total of 14 million shares	14/02
Hvivo Shareholders Plan Secondary Placing to Sell 14 Million Shares	14/02
FTSE 100 Ends on Three-Week High, Partly on Diageo Rebound	30/01
HVIVO shares up after "record year" across all metrics	30/01
Hvivo Wins GBP6 Million Antiviral Testing Contract	02/01
HVIVO inks GBP6.3 million deal to test common cold treatment	02/01
New Year begins largely green amid slew of PMIs	02/01
HVIVO plc Signs £6.3 Million Human Challenge Study Model	02/01

Aucun résultat pour cette recherche